PPARG: A New Independent Marker for Colorectal Cancer Survival

Gastroenterology

Volumn 136, Issue 4, 2009, Pages 1157-1160

  Girnun, Geoffrey ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; DIABETES MELLITUS; EDITORIAL; FAT INTAKE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE;

EID: 62949228303     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.02.022     Document Type: Editorial

References (32)

1. Society A.C. Cancer facts and figures (2008), American Cancer Society, Atlanta
2. Calle E.E., and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4 (2004) 579-591
3. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (2003) 1625-1638
4. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94 (1997) 4312-4317
5. Kliewer S.A., Sundseth S.S., Jones S.A., et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 94 (1997) 4318-4323
6. Ogino S., Shima K., Baba Y., et al. Colorectal cancer expression of PPARG (peroxisome proliferator-activated receptor-gamma) is associated with good prognosis. Gastroenterology 136 (2009) 1242-1250
7. Tontonoz P., and Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77 (2008) 289-312
8. Straus D.S., and Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28 (2007) 551-558
9. Michalik L., Desvergne B., and Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4 (2004) 61-70
10. Tontonoz P., Hu E., and Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 (1994) 1147-1156
11. Lehmann J.M., Moore L.B., Smith-Oliver T.A., et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270 (1995) 12953-12956
12. DuBois R.N., Gupta R., Brockman J., et al. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 19 (1998) 49-53
13. Sarraf P., Mueller E., Jones D., et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4 (1998) 1046-1052
14. Brockman J.A., Gupta R.A., and Dubois R.N. Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115 (1998) 1049-1055
15. Lefebvre A.M., Chen I., Desreumaux P., et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 4 (1998) 1053-1057
16. Saez E., Tontonoz P., Nelson M.C., et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4 (1998) 1058-1061
17. Girnun G.D., Smith W.M., Drori S., et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A 99 (2002) 13771-13776
18. Kulke M.H., Demetri G.D., Sharpless N.E., et al. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 8 (2002) 395-399
19. Govindarajan R., Ratnasinghe L., Simmons D.L., et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25 (2007) 1476-1481
20. Lewis J.D., Capra A.M., Achacoso N.S., et al. Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus. Gastroenterology 135 (2008) 1914-1923
21. Gustafsson A., Hansson E., Kressner U., et al. EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer 121 (2007) 232-240
22. Theocharis S., Giaginis C., Parasi A., et al. Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival. Dig Dis Sci 52 (2007) 2305-2311
23. Grady W.M., and Carethers J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135 (2008) 1079-1099
24. Lu H., Ouyang W., and Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 4 (2006) 221-233
25. Allavena P., Garlanda C., Borrello M.G., et al. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 18 (2008) 3-10
26. Wu G.D. Nuclear hormone receptors and intestinal inflammation. Gastroenterology 133 (2007) 1068
27. Szeles L., Torocsik D., and Nagy L. PPARgamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta 1771 (2007) 1014-1030
28. Bren-Mattison Y., Meyer A.M., Van Putten V., et al. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 73 (2008) 709-717
29. Zhang Y.Q., Tang X.Q., Sun L., et al. Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J Gastroenterol 13 (2007) 1534-1540
30. Reddy R.C., Srirangam A., Reddy K., et al. Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer. Neoplasia 10 (2008) 597-603
31. Girnun G.D., Naseri E., Vafai S.B., et al. Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 11 (2007) 395-406
32. Girnun G.D., Chen L., Silvaggi J., et al. Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res 14 (2008) 6478-6486